Together, our data suggest that targeting NF-κB activation reduces the expression of its target genes (e.g., CD44, BCL-XL,and cMyc) and subsequently affects proliferation and invasiveness of triple negative breast cancer cells. The gene discussed is NFKB1; the disease is triple-negative breast carcinoma.